Literature DB >> 20171172

Mechanism of action of the HIV-1 integrase inhibitory peptide LEDGF 361-370.

Zvi Hayouka1, Aviad Levin, Michal Maes, Eran Hadas, Deborah E Shalev, David J Volsky, Abraham Loyter, Assaf Friedler.   

Abstract

The HIV-1 integrase protein (IN) mediates integration of the viral cDNA into the host genome and is a target for anti-HIV drugs. We have recently described a peptide derived from residues 361-370 of the IN cellular partner protein LEDGF/p75, which inhibited IN catalytic activity in vitro and HIV-1 replication in cells. Here we performed a comprehensive study of the LEDGF 361-370 mechanism of action in vitro, in cells and in vivo. Alanine scan, fluorescence anisotropy binding studies, homology modeling and NMR studies demonstrated that all residues in LEDGF 361-370 contribute to IN binding and inhibition. Kinetic studies in cells showed that LEDGF 361-370 specifically inhibited integration of viral cDNA. Thus, the full peptide was chosen for in vivo studies, in which it inhibited the production of HIV-1 RNA in mouse model. We conclude that the full LEDGF 361-370 peptide is a potent HIV-1 inhibitor and may be used for further development as an anti-HIV lead compound. 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20171172     DOI: 10.1016/j.bbrc.2010.02.100

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  8 in total

1.  Prospective strategies for targeting HIV-1 integrase function.

Authors:  Yang Luo; Mark A Muesing
Journal:  Future Med Chem       Date:  2010-07       Impact factor: 3.808

Review 2.  Strategies to inhibit viral protein nuclear import: HIV-1 as a target.

Authors:  Aviad Levin; Abraham Loyter; Michael Bukrinsky
Journal:  Biochim Biophys Acta       Date:  2010-08-16

3.  Specific recognition of p53 tetramers by peptides derived from p53 interacting proteins.

Authors:  Ronen Gabizon; Tobias Brandt; Shahar Sukenik; Noa Lahav; Mario Lebendiker; Deborah E Shalev; Dmitry Veprintsev; Assaf Friedler
Journal:  PLoS One       Date:  2012-05-31       Impact factor: 3.240

4.  Inhibiting the HIV integration process: past, present, and the future.

Authors:  Roberto Di Santo
Journal:  J Med Chem       Date:  2013-09-25       Impact factor: 7.446

Review 5.  Allosteric modulation of protein oligomerization: an emerging approach to drug design.

Authors:  Ronen Gabizon; Assaf Friedler
Journal:  Front Chem       Date:  2014-03-24       Impact factor: 5.221

Review 6.  Different Pathways Leading to Integrase Inhibitors Resistance.

Authors:  Eloïse Thierry; Eric Deprez; Olivier Delelis
Journal:  Front Microbiol       Date:  2017-01-11       Impact factor: 5.640

Review 7.  Host-HIV-1 Interactome: A Quest for Novel Therapeutic Intervention.

Authors:  Ekta Shukla; Radha Chauhan
Journal:  Cells       Date:  2019-09-27       Impact factor: 6.600

8.  Structural Characterization of the Loop at the Alpha-Subunit C-Terminus of the Mixed Lineage Leukemia Protein Activating Protease Taspase1.

Authors:  Johannes van den Boom; Franziska Trusch; Lukas Hoppstock; Christine Beuck; Peter Bayer
Journal:  PLoS One       Date:  2016-03-14       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.